Dynamics of mandibular density during therapy with zolendronic acid

Nurieva N.S.; Shelegova I.G.; Fanakin V.A.

doi:https://doi.org/10.17116/stomat202410304133

Nurieva N.S.

South-Urals State Medical University of the Ministry of Healthcare of the Russian Federation

SPIN RSCI: 9776-3982
Scopus AuthorID: 55303881200
ORCID: 0000-0002-5656-2286

Shelegova I.G.

South-Urals State Medical University

ORCID: 0000-0002-8381-2535

Fanakin V.A.

South Ural State Medical University

ORCID: 0009-0002-5860-2226

Dynamics of mandibular density during therapy with zolendronic acid

Authors:

Nurieva N.S., Shelegova I.G., Fanakin V.A.

More about the authors

Journal: Stomatology. 2024;103(4): 33‑36

DOI: 10.17116/stomat202410304133

Read: 1019 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Nurieva NS, Shelegova IG, Fanakin VA. Dynamics of mandibular density during therapy with zolendronic acid. Stomatology. 2024;103(4):33‑36. (In Russ.)
https://doi.org/10.17116/stomat202410304133

Подписка 2026 Стоматология (Stomatology)

Использование инфографики авторами научных работ

Close metadata

THE AIM OF THE STUDY

Was to investigate the dynamics of mandibular density in cancer patients during therapy with zolendronic acid.

MATERIALS AND METHODS

The study comprised 14 patients who received zolendronic acid at a dosage of 4 mg once every 28 days for bone metastases. In all 14 patients, measurements of mandibular density values on CT scans were performed over time.

RESULTS

Using multiple linear regression analysis, a model was developed to predict the effect of the number of zolendronic acid injections «X₁» on the dynamics of mandibular density «Y». The resulting formula for predicting mandibular density is Y = 5.9 X₁ + 49 HU.

CONCLUSION

The model has limitations due to the study design but still can be used by oncologists and dentists to assess mandibular density in patients taking zolendronic acid.

Keywords:

osteomodifying agents

bisphosphonates

bone metastases

optical density

zolendronic acid

mandible

Authors:

Nurieva N.S.

South-Urals State Medical University of the Ministry of Healthcare of the Russian Federation

SPIN RSCI: 9776-3982
Scopus AuthorID: 55303881200
ORCID: 0000-0002-5656-2286

Shelegova I.G.

South-Urals State Medical University

ORCID: 0000-0002-8381-2535

Fanakin V.A.

South Ural State Medical University

ORCID: 0009-0002-5860-2226

Received:

20.12.2023

Accepted:

22.05.2024

Close metadata

References:

Vinogradova N, Solomatina L, Kharitonova M, L’vov K, Borzunov D. Optical bone density as a prognostic risk factor for the development of medication-related osteonecrosis of the jaw in patients with bone metastases. Genij Ortopedii. 2020;26(4):539-543. (In Russ.). https://doi.org/10.18019/1028-4427-2020-26-4-539-543
Lesniak OM. Osteonecrosis of the jaw on antiresorptive therapy of osteoporosis: prevention, diagnosis, patient management. Osteoporosis and Osteopathies. 2023;26(1):4-12. (In Russ.). https://doi.org/10.14341/osteo13135
Matys T. Medication-related osteonecrosis of the jaw. Radiology. 2021; 301(3):548. https://doi.org/10.1148/radiol.2021211142
Ruggiero SL, Dodson TB, Fantasia J, et al. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw — 2014 update. J Oral Maxillofac Surg. 2014;72(10):1938-1956. https://doi.org/10.1016/j.joms.2022.02.008
Wu S, Li F, Tan J, Ye X, Le Y, Liu N, Everts V, Wan Q. Porphyromonas gingivalis Induces Bisphosphonate-Related Osteonecrosis of the Femur in Mice. Front Cell Infect Microbiol. 2022;12:886411. https://doi.org/10.3389/fcimb.2022.886411
Ebzeyev AK. Bisphosphonate osteonecrosis of the jaws in oncologic patients. Kazan Medical Journal. 2020;101(2),226-231. (In Russ.). https://doi.org/10.17816/KMJ2020-226
Loktionova MV, Gabbasova IV, Sletova VA, Muratova AY, Sletov AA, Zhidovinov AV. Dynamics of amino acid indices in an experimental model of bisphosphonate osteonecrosis. Institute of Stomatology. 2022;95(2):99-100. (In Russ.).
Beth-Tasdogan NH, Mayer B, Hussein H, Zolk O, Peter JU. Interventions for managing medication-related osteonecrosis of the jaw. Cochrane Database Syst Rev. 2022;7(7):CD012432. https://doi.org/10.1002/14651858.CD012432.pub3
Reinert CP, Pfannenberg C, Gatidis S, la Fougère C, Nikolaou K, Hoefert S. 18F-Fluoride PET/CT Imaging of Medication-Related Osteonecrosis of the Jaw in Conservative Treatment-A Case Report. Frontiers in oncology. 2021;11:700397. https://doi.org/10.3389/fonc.2021.700397
Watanabe S, Nakajima K, Kinuya S. Symposium: Imaging modalities for drug-related osteonecrosis of the jaw (5), utility of bone scintigraphy and 18F-FDG PET/CT in early detection and risk assessment of medication-related osteonecrosis of the jaw (secondary publication). The Japanese dental science review. 2019;55(1):76-79. https://doi.org/10.1016/j.jdsr.2018.12.002
Kitagawa Y, Ohga N, Asaka T, Sato J, Hata H, Helman J, Tsuboi K, Amizuka N, Kuge Y, Shiga T. Imaging modalities for drug-related osteonecrosis of the jaw (3), Positron emission tomography imaging for the diagnosis of medication-related osteonecrosis of the jaw. The Japanese dental science review. 2019;55(1):65-70. https://doi.org/10.1016/j.jdsr.2018.12.001
Fushimi M, Ohbayashi Y, Nakai F, Norikane T, Yamamoto Y, Nishiyama Y, Miyake M. The effect of zoledronic acid and denosumab on the mandible and other bones: a 18F-NaF-PET study. Oral radiology. 2022; 38(4):594-600. https://doi.org/10.1007/s11282-022-00594-2
Sharashova EE, Kholmatova KK, Gorbatova MA, Grjibovski AM. Application of multiple linear regression analysis in health care using the spss statistical software package. Science &Healthcare. 2017;3:5-31. (In Russ.).
Lang Thomas A, Secic Michelle. How to report statistics in medicine. Annotated guidelines for authors,editors and reviewers. Translation from English edited by Leonov V.P. M.: Practical Medicine; 2011. (In Russ.).